

Erratum to: “Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia”

Salih Demir,^{1,2} Elena Boldrin,¹⁻³ Qian Sun,¹ Stephanie Hampp,⁴ Eugen Tausch,⁵ Cornelia Eckert,⁶ Martin Ebinger,⁷ Rupert Handgretinger,⁷ Geertruy te Kronnie,⁸ Lisa Wiesmüller,⁴ Stephan Stilgenbauer,⁵ Galina Selivanova,⁹ Klaus-Michael Debatin¹ and Lüder Hinrich Meyer¹

¹Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany; ²International Graduate School of Molecular Medicine, Ulm University, Ulm, Germany; ³PhD Program in Biosciences, University of Padova, Padova, Italy; ⁴Department of Obstetrics and Gynecology, Ulm University Medical Center, Ulm, Germany; ⁵Department of Internal Medicine III, Ulm University Medical Center, Ulm, Germany; ⁶Department of Pediatrics, Charité Center Gynecology, Perinatal, Pediatric and Adolescent Medicine, Berlin, Germany; ⁷Department of General Pediatrics, Hematology and Oncology, Children’s University Hospital Tübingen, Tübingen, Germany; ⁸Department of Women’s and Children’s Health, University of Padova, Padova, Italy and ⁹Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden

Correspondence: L.H. Meyer
lueder-hinrich.meyer@uniklinik-ulm.de
Received: June 3, 2026.
Accepted: June 3, 2026.

<https://doi.org/10.3324/haematol.2026.289473>
©2026 Ferrata Storti Foundation
Published under a CC BY-NC license

In the published version of our article,¹ there was a potential error and an omission.

(1) Figure 3C, PUMA and p21 panels.
By mistake, the p21 bands might have been included in Figure 3C instead of the PUMA bands. We correct this potential mistake and show here the correct western blot data with the relevant part of the legend.

(2) Conflicts of interest
A conflict-of-interest statement was provided by the authors and present in the version of the manuscript published online ahead of print (May 9, 2019), but by mistake of the publisher was not included in the finally published article. The omitted Disclosures statement is shown below.

Disclosures
GS is a co-founder and shareholder of Aprea Therapeutics, a company developing p53-based cancer therapy including APR-246. All other authors declare that no conflicts of interest exist.

References

1. Demir S, Boldrin E, Sun Q, et al. Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(1):170-181.

